



NATIONAL
QUALITY FORUM

1030 15TH STREET, NW, SUITE 800
WASHINGTON, DC 20005
202 783-1300 MAIN 783-3434 FAX

**Cardiovascular Measure Endorsement Project 2015
Standing Committee Meeting
September 9 -10, 2015**

National Quality Forum
Executive Building
1030 15th Street, NW, Suite 900
Washington, DC 20005
(202) 783-1300

Please use the following information to access the conference call line and webinar:

Day1:

Speaker Dial-in #: 1-888-802-7237

Public Dial-in #: 1-877-303-9138

Conference ID #: 88997583

Web Link Day #1: <http://nqf.commpartners.com/se/NOFLogin/>

Web Meeting ID#1: 822677

Day2:

Speaker Dial-in #: 1-888-802-7237

Public Dial-in #: 1-877-303-9138

Conference ID #: 88999428

Web Link Day #2: <http://nqf.commpartners.com/se/NOFLogin/>

Web Meeting ID#2: 913449

AGENDA

Day 1: September 9, 2015

8:30 am **Continental Breakfast**

9:00 am **Welcome**
Mary George, MD, MSPH, FACS, FAHA (co-chair)
Thomas Kottke, MD, MSPH (co-chair)
Melissa Mariñelarena, RN, MPA, Senior Director
Leslie Vicale, MPH, Project Manager

9:05 am	Introductions and Disclosure of Interest Ann Hammersmith, JD, General Counsel
9:15 am	Portfolio Overview Melissa Mariñelarena, RN, MPA, Senior Director Leslie Vicale, MPH, Project Manager
9:25 am	Updates to Process for Measure Evaluation Melissa Mariñelarena, RN, MPA, Senior Director Karen Johnson, MS, PhD(c), Senior Director
9:45 am	Ad-Hoc Discussion <ul style="list-style-type: none"> 0018: <i>Controlling High Blood Pressure (CBP)</i> (NCQA)
10:15 pm	NQF Member and Public Comment
10:30 am	Break
10:45 am	Consideration of Candidate Measures Mary George, MD, MSPH, FACS, FAHA (co-chair) Thomas Kottke, MD, MSPH (co-chair) <ul style="list-style-type: none"> 0068: <i>Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic</i> (NCQA) 0071: <i>Persistence of Beta-Blocker Treatment After a Heart Attack</i> (NCQA)
11:45 am	Composite Measures Karen Johnson, MS, PhD(c), Senior Director
12:00 pm	Consideration of Candidate Measures (Continued) <ul style="list-style-type: none"> 0694: <i>Hospital Risk-Standardized Complication Rate following Implantation of Implantable Cardioverter-Defibrillator (ICD)</i> (ACC) 2764: <i>(eMeasure) Fixed Dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure with LVEF <40% on ACE/ARB or Beta-blocker Therapy</i> (NMQF)
1:00 pm	Lunch
1:30 pm	Consideration of Candidate Measures (Continued) <ul style="list-style-type: none"> 0730: <i>Acute Myocardial Infarction (AMI) Mortality Rate</i> (AHRQ)

- 2396: *Evaluation of Vital Status and NIH Stroke Scale at Follow-Up* (ACC)
- 0965: *Patients with an ICD implant who receive ACE-I/ARB and beta blocker therapy at discharge* (ACC)
- 2712: *Statin Use in Persons with Diabetes* (PQA)

3:00 pm **Break**

3:15 pm **Consideration of Candidate Measures (Continued)**

- 0669: *Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac, Low Risk Surgery* (CMS/Yale CORE)
- 0230: *Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following acute myocardial infarction (AMI) hospitalization for patients 18 and older* (CMS/Yale CORE)
- 0229: *Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following heart failure (HF) hospitalization for patients 18 and older.* (CMS/Yale CORE)

4:45 pm **NQF Member and Public Comment**

5:00 pm **Adjourn**

Day 2: September 10, 2015

8:00 am **Continental Breakfast**

8:30 am **Welcome, Recap of Day 1**
Mary George, MD, MSPH, FACS, FAHA (co-chair)
Thomas Kottke, MD, MSPH (co-chair)

8:35 am **Measure Evaluation Process Recap**
Melissa Mariñelarena, RN, MPA, Senior Director

8:45 am **Consideration of Candidate Measures (Continued)**

- 0070: *(eMeasure) Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)* (AMA-PCPI)
- 0081: *(eMeasure) Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)* (AMA-PCPI)
- 0083: *(eMeasure) Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)* (AMA-PCPI)

10:15 am	Break
10:30 am	Consideration of Candidate Measures (Continued) <ul style="list-style-type: none"> • 2740: <i>Proportion of Patients with coronary artery disease (CAD) that have a Potentially Avoidable Complication (during the episode time window)</i> (HCl3) • 2747: <i>Proportion of Patients with Heart Failure (HF) that have a Potentially Avoidable Complication (during the episode time window)</i> (HCl3) • 2748: <i>Proportion of Patients with Hypertension (HTN) that have a Potentially Avoidable Complication (during the episode time window)</i> (HCl3)
12:30 pm	Lunch
1:00 pm	Consideration of Candidate Measures (Continued) <ul style="list-style-type: none"> • 2749: <i>Proportion of Patients with Arrhythmias (ARR) that have a Potentially Avoidable Complication (during the episode time window)</i> (HCl3) • 2751: <i>Proportion of Patients undergoing an Angioplasty Procedure (Percutaneous Coronary Intervention - PCI) that have a Potentially Avoidable Complication (during the episode time window)</i> (HCl3) • 2752 : <i>Proportion of Patients undergoing Pacemaker / Defibrillator Implantation (PCMDFR) that have a Potentially Avoidable Complication (during the episode time window)</i> (HCl3)
2:00 pm	Break
2:15 pm	Consideration of Candidate Measures (Continued) <ul style="list-style-type: none"> • 0067: <i>Chronic Stable Coronary Artery Disease: Antiplatelet Therapy</i> (ACC) • 0079: <i>Heart Failure: Left Ventricular Ejection Fraction Assessment (Outpatient Setting)</i> (ACC) • 2763: <i>Ischemic Vascular Disease Care: All or None Outcome Measure-Optimal Control</i> (WCHQ)
3:45 pm	NQF Member and Public Comment
4:00 pm	Next Steps Leslie Vicale, MPH, Project Manager
4:10 pm	Adjourn